[ HARMONIZER — NOT A MARKET ]
The veterinary counterpart to ICH, harmonising the technical requirements that apply to veterinary medicinal products.
SPEQ synthesis for orientation. It does not determine what applies to a specific product, and an adopted version can move without this page moving with it. Confirm the instrument in force with the authority before relying on it.
INTERNATIONAL
None of its own. VICH — International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products — was formed in April 1996, triggered by the OIE, now the World Organisation for Animal Health, and holding its first Steering Committee meeting in Paris that month. It is a programme of collaboration between the regulatory authorities and animal-health industries of three regions: the European Union, Japan and the United States. Canada and Australia/New Zealand hold observer status. It publishes guidelines and enacts nothing.
By regional implementation, exactly as ICH’s do. In the United States, FDA’s Center for Veterinary Medicine issues VICH guidelines as Guidance for Industry documents — VICH GL9 as GFI #85, VICH GL6 as GFI #89 — and the guidance is what a sponsor works to. The European Union implements them through its veterinary framework, and Japan through its own authority. The goal is narrow and clearly stated: harmonising the technical data requirements the three participating authorities apply before granting a marketing authorisation.
WHAT TRANSFERS
The study package, in principle. Harmonised technical requirements mean a study designed to a VICH guideline is intended to be acceptable to all three regions, which is what reduces duplicated animal testing — an outcome VICH names explicitly and one that matters for reasons beyond cost. What does not transfer is the authorisation. Each region grants its own, and the observer regions have not thereby adopted anything: observer status is participation in the work, not implementation of its output.
It is the veterinary analogue of ICH E6, covering the design, conduct, monitoring, recording and reporting of clinical studies supporting a veterinary product’s safety and efficacy, together with sponsor, monitor and investigator responsibilities and the animal-welfare and owner-consent considerations that have no human counterpart. FDA CVM adopts it as GFI #85. It is not a non-clinical standard, and mistaking it for one is a scope error that reads perfectly.
The European Union, Japan and the United States participate; Canada and Australia/New Zealand observe. Guidelines are made available for wider use, but availability is not adoption, and a market outside the three has whatever national requirements it has.
Veterinary clinical work inherits the structure of human GCP and changes who consents, who is protected and what has to be recorded — including, for food-producing animals, the withdrawal obligation and the exposure of humans handling the product. The framework is familiar; the obligations it carries are not the same.
For a submission or an inspection response, the citable document is the regional implementation — CVM GFI #85 rather than VICH GL9 in the United States. The VICH number identifies the harmonised text; the regional number identifies what applies.
The International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products, formed in April 1996 at the instigation of the OIE — now the World Organisation for Animal Health. It brings together the regulatory authorities and animal-health industries of the European Union, Japan and the United States, with Canada and Australia/New Zealand as observers.
Good Clinical Practice for veterinary clinical studies — the design, conduct, monitoring, recording and reporting of studies supporting the safety and efficacy of veterinary medicinal products, and the responsibilities of sponsor, monitor and investigator. It is the veterinary analogue of ICH E6, and FDA’s Center for Veterinary Medicine adopts it as Guidance for Industry #85.
Not in themselves. VICH publishes harmonised guidelines; they take effect through regional implementation — as FDA CVM Guidance for Industry documents in the United States, through the EU veterinary framework, and through Japan’s own authority. For a regulatory commitment, cite the regional instrument.
That is the intent: harmonised technical data requirements mean a study designed to a VICH guideline should be acceptable across the three participating regions, which is how the programme reduces duplicated animal testing. It does not produce a single authorisation — each region still grants its own on its own terms.
ADOPTED, AT A PINNED VERSION
SPEQ has not decoded a pinned adoption edge here yet. That is a gap in this catalog, not a finding about VICH: requirements still arrive through the authorities that adopt this body’s output, and the edition in force is theirs to state.
SPEQ records no harmonizer participation for VICH. Requirements here are set by the authorities above rather than arriving through a harmonized guide, so evidence prepared for another market does not transfer on that basis.